JNJ vs SNN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: SNN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and SNN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and SNN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Smith & Nephew sells implants and consumables into the operating room and the wound clinic, and it runs three global business units. Orthopaedics, the largest at $2,437 million of 2025 revenue, covers knee implants, hip implants, other reconstruction and a trauma and extremities line. Sports Medicine & ENT, $1,934 million in 2025, sells arthroscopic repair systems, the REGENETEN bioinductive implant for rotator cuff repair, visualisation and resection hardware, and ear, nose and throat instruments. Advanced Wound Management, $1,793 million, spans foam and antimicrobial dressings, negative pressure wound therapy devices such as PICO and RENASYS, and a bioactives portfolio that includes SANTYL and skin substitutes. Group revenue was $6,164 million in 2025, up 6.1% reported and 5.3% underlying, and the business employs roughly 17,000 people. Around half of sales come from the United States: US revenue was $1,591 million of the $3,097 million booked in the first half of 2026. Emerging markets, where the company grew 10.6% underlying in that half, are the fastest-moving geography and also the source of the China pricing risk described below. The customer is a hospital or a surgical centre, the sale is usually a consumable or an implant rather than a capital item, and revenue is therefore closely tied to elective procedure volumes in the United States, Europe and Japan.

Full SNN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• SNN drivers: Sports Medicine is doing the compounding; Orthopaedics margin ahead of Orthopaedics revenue.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For SNN, the clearest risk is that US Orthopaedics does not turn.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; SNN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and SNN guides.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

SNN. The multiple sits well below the large-cap orthopaedic peer group, and the reason is visible in the segment table rather than in any accounting subtlety: the largest franchise earns the lowest margin and is not growing. Investors buying at ~14 times adjusted earnings are paying for the RISE targets to close that gap, or for someone to force the issue on portfolio structure.

Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; SNN shows revenue (ttm) ~$6.30 billion for the twelve months to June 27, 2026, derived from 2025 revenue of $6,164 million plus first-half 2026 revenue of $3,097 million less first-half 2025 revenue of $2,961 million. Full-year 2025 revenue grew 6.1% reported and 5.3% underlying, from $5,810 million in 2024 and $5,549 million in 2023. First-half 2026 growth was 4.6% reported but only 2.3% underlying, with a 230 basis point currency tailwind and one fewer trading day. Everything here is reported in US dollars, the company's actual reporting currency, so no conversion from sterling is involved., earnings and adjusted earnings Attributable profit of ~$635 million for the twelve months to June 27, 2026, giving basic EPS of ~74.2 cents per ordinary share, or roughly $1.48 per ADS at the two-for-one ratio. Full-year 2025 EPS was 72.1 cents, up 52.8%, on operating profit of $794 million. The company's preferred measure runs well above that: trading profit was $1,211 million in 2025 (19.7% margin) and ~$1,254 million on a trailing basis, with adjusted EPS of 102.0 cents per ordinary share in 2025 and ~106.8 cents trailing, about $2.14 per ADS. The gap between operating and trading profit, roughly $440 million, is restructuring, acquisition amortisation and legal items., franchise mix and margins 2025 revenue split Orthopaedics $2,437 million, Sports Medicine & ENT $1,934 million and Advanced Wound Management $1,793 million, with segment trading margins of 14.9%, 23.8% and 24.9% respectively. In the first half of 2026 that became Orthopaedics $1,213 million (down 0.1% underlying, 13.0% margin), Sports Medicine & ENT $1,017 million (up 7.7%, 24.7% margin) and Advanced Wound Management $867 million (down 0.1% underlying, 22.0% margin). Geographically, US revenue was $1,591 million of the $3,097 million half, other established markets $958 million, and emerging markets $548 million growing 10.6% underlying., cash flow and balance sheet Free cash flow of ~$823 million on a trailing basis, after $836 million in 2025 against a $625 million internal target. First-half 2026 cash from operations was $605 million, up 6.9%, while free cash flow slipped to $231 million on ~$51 million of extra capex for a new UK wound factory and IT upgrades. Net debt was $3,019 million at June 27, 2026 (including $197 million of lease liabilities), up from $2,747 million at December 31, 2025, and adjusted net debt to EBITDA was 1.8 times. In June 2026 the group issued a EUR 500 million 4.25% bond due 2038. Nothing matures in the second half of 2026; $350 million of corporate bonds and $140 million of private placement notes fall due in the first half of 2027..

JNJ and SNN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and SNN exposure against your real portfolio. It is not an investment adviser.